Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms

Ajit Bisen, David Claxton

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Citations (Scopus)

Abstract

Myeloproliferative neoplasms (MPNs) include Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) and the Ph- diseases primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET). Since FDA approval of imatinib in 2001, CML treatment has been focused on tyrosine kinase inhibitors. With these targeted therapies, imatinib-resistant CML has emerged as a major problem. Second generation tyrosine kinase inhibitors (TKIs) have allowed for effective treatment of some patients with imatinib resistance, but bcr-abl mutants such as T315I remain problematic. Additional agents are in development and are discussed here. New clinical issues with TKI treatment include premature termination of therapy due to adverse-effects, the cost of therapy, and the apparently indefinite duration of treatment in patients who have achieved complete molecular response (CMR). In contrast to Ph+ CML, targeted therapy for Ph- MPNs is novel and of less clear therapeutic potential. New insights into Ph- MPNs include alterations in the JAK-STAT signaling pathway, particularly as mediated by the JAK2 V617F mutation. The recent development of multiple JAK2 inhibitors has provided hope for the rational and effective management of these disorders. Recently, ruxolitinib was approved as therapy for PMF. Current data suggests, however, that given its vital cell signaling function, the therapeutic benefit of targeting Jak kinases in general, or JAK2 specifically may be less than that derived from ABL-directed TKI treatment of CML. This review focuses on the current treatment options for CML and Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) and limitations faced in current clinical practice.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages179-196
Number of pages18
DOIs
StatePublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Chromosomes
Neoplasms
Cell signaling
Therapeutics
Phosphotransferases
Philadelphia Chromosome
Polycythemia Vera
Primary Myelofibrosis
Imatinib Mesylate
Costs
Essential Thrombocythemia

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bisen, A., & Claxton, D. (2013). Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 179-196). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-8
Bisen, Ajit ; Claxton, David. / Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Impact of Genetic Targets on Cancer Therapy. editor / Wafik El-Deiry. 2013. pp. 179-196 (Advances in Experimental Medicine and Biology).
@inbook{a00a0a9da2bf413d8762f39253fc5769,
title = "Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms",
abstract = "Myeloproliferative neoplasms (MPNs) include Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) and the Ph- diseases primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET). Since FDA approval of imatinib in 2001, CML treatment has been focused on tyrosine kinase inhibitors. With these targeted therapies, imatinib-resistant CML has emerged as a major problem. Second generation tyrosine kinase inhibitors (TKIs) have allowed for effective treatment of some patients with imatinib resistance, but bcr-abl mutants such as T315I remain problematic. Additional agents are in development and are discussed here. New clinical issues with TKI treatment include premature termination of therapy due to adverse-effects, the cost of therapy, and the apparently indefinite duration of treatment in patients who have achieved complete molecular response (CMR). In contrast to Ph+ CML, targeted therapy for Ph- MPNs is novel and of less clear therapeutic potential. New insights into Ph- MPNs include alterations in the JAK-STAT signaling pathway, particularly as mediated by the JAK2 V617F mutation. The recent development of multiple JAK2 inhibitors has provided hope for the rational and effective management of these disorders. Recently, ruxolitinib was approved as therapy for PMF. Current data suggests, however, that given its vital cell signaling function, the therapeutic benefit of targeting Jak kinases in general, or JAK2 specifically may be less than that derived from ABL-directed TKI treatment of CML. This review focuses on the current treatment options for CML and Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) and limitations faced in current clinical practice.",
author = "Ajit Bisen and David Claxton",
year = "2013",
month = "2",
day = "15",
doi = "10.1007/978-1-4614-6176-0-8",
language = "English (US)",
isbn = "9781461461753",
series = "Advances in Experimental Medicine and Biology",
pages = "179--196",
editor = "Wafik El-Deiry",
booktitle = "Impact of Genetic Targets on Cancer Therapy",

}

Bisen, A & Claxton, D 2013, Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. in W El-Deiry (ed.), Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, vol. 779, pp. 179-196. https://doi.org/10.1007/978-1-4614-6176-0-8

Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. / Bisen, Ajit; Claxton, David.

Impact of Genetic Targets on Cancer Therapy. ed. / Wafik El-Deiry. 2013. p. 179-196 (Advances in Experimental Medicine and Biology; Vol. 779).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms

AU - Bisen, Ajit

AU - Claxton, David

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Myeloproliferative neoplasms (MPNs) include Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) and the Ph- diseases primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET). Since FDA approval of imatinib in 2001, CML treatment has been focused on tyrosine kinase inhibitors. With these targeted therapies, imatinib-resistant CML has emerged as a major problem. Second generation tyrosine kinase inhibitors (TKIs) have allowed for effective treatment of some patients with imatinib resistance, but bcr-abl mutants such as T315I remain problematic. Additional agents are in development and are discussed here. New clinical issues with TKI treatment include premature termination of therapy due to adverse-effects, the cost of therapy, and the apparently indefinite duration of treatment in patients who have achieved complete molecular response (CMR). In contrast to Ph+ CML, targeted therapy for Ph- MPNs is novel and of less clear therapeutic potential. New insights into Ph- MPNs include alterations in the JAK-STAT signaling pathway, particularly as mediated by the JAK2 V617F mutation. The recent development of multiple JAK2 inhibitors has provided hope for the rational and effective management of these disorders. Recently, ruxolitinib was approved as therapy for PMF. Current data suggests, however, that given its vital cell signaling function, the therapeutic benefit of targeting Jak kinases in general, or JAK2 specifically may be less than that derived from ABL-directed TKI treatment of CML. This review focuses on the current treatment options for CML and Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) and limitations faced in current clinical practice.

AB - Myeloproliferative neoplasms (MPNs) include Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) and the Ph- diseases primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET). Since FDA approval of imatinib in 2001, CML treatment has been focused on tyrosine kinase inhibitors. With these targeted therapies, imatinib-resistant CML has emerged as a major problem. Second generation tyrosine kinase inhibitors (TKIs) have allowed for effective treatment of some patients with imatinib resistance, but bcr-abl mutants such as T315I remain problematic. Additional agents are in development and are discussed here. New clinical issues with TKI treatment include premature termination of therapy due to adverse-effects, the cost of therapy, and the apparently indefinite duration of treatment in patients who have achieved complete molecular response (CMR). In contrast to Ph+ CML, targeted therapy for Ph- MPNs is novel and of less clear therapeutic potential. New insights into Ph- MPNs include alterations in the JAK-STAT signaling pathway, particularly as mediated by the JAK2 V617F mutation. The recent development of multiple JAK2 inhibitors has provided hope for the rational and effective management of these disorders. Recently, ruxolitinib was approved as therapy for PMF. Current data suggests, however, that given its vital cell signaling function, the therapeutic benefit of targeting Jak kinases in general, or JAK2 specifically may be less than that derived from ABL-directed TKI treatment of CML. This review focuses on the current treatment options for CML and Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) and limitations faced in current clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84873574869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873574869&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6176-0-8

DO - 10.1007/978-1-4614-6176-0-8

M3 - Chapter

C2 - 23288640

AN - SCOPUS:84873574869

SN - 9781461461753

T3 - Advances in Experimental Medicine and Biology

SP - 179

EP - 196

BT - Impact of Genetic Targets on Cancer Therapy

A2 - El-Deiry, Wafik

ER -

Bisen A, Claxton D. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. In El-Deiry W, editor, Impact of Genetic Targets on Cancer Therapy. 2013. p. 179-196. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-6176-0-8